Transcatheter Aortic Valve Replacement with Self-Expandable ACURATE neo as compared to Balloon-Expandable SAPIEN 3 in Patients with Severe Aortic Stenosis: Meta-analysis of Randomized and Propensity-Matched Studies. J. Clin. Med. 2020, 9, 397

The authors sincerely apologise for the imperfections made during the collection of the data and wish to make the following corrections to this paper [...].

(2) Abstract In conclusion, ACURATE neo, as compared with SAPIEN 3, was associated with higher rates of moderate-to-severe PVL, which were indirectly linked with increased observed 30-day all-cause mortality.

Should be replaced with
In conclusion, ACURATE neo, as compared with SAPIEN 3, was associated with higher rates of moderate-to-severe PVL, which were further linked to increased observed 30-day all-cause mortality.
(2) Abstract In conclusion, ACURATE neo, as compared with SAPIEN 3, was associated with higher rates of moderate-to-severe PVL, which were indirectly linked with increased observed 30-day all-cause mortality.

Should be replaced with
In conclusion, ACURATE neo, as compared with SAPIEN 3, was associated with higher rates of moderate-to-severe PVL, which were further linked to increased observed 30-day all-cause mortality. (
(7) 4. Discussion The abovementioned improvements seen in next-generation devices seem not to be the case with ACURATE neo; in the meta-analysis, we found 11.7% incidence of moderate-to-severe PVL in the ACURATE neo arm, nearly fourfold higher than in SAPIEN 3 and mild PVL in 45.5% cases, translating into 60% increased risk.
Should be replaced with: (6) 3.6. All-Cause Mortality A random-effects meta-regression was fitted, counter-opposing all-cause mortality risk ratio against the risk difference of moderate-to-severe PVL; there was a trend for higher 30-day mortality rates with higher incidence of moderate-to-severe PVL (beta = 0.023; P = 0.093) ( Figure 5b); Should be replaced with: A random-effects meta-regression was fitted, counter-opposing all-cause mortality risk ratio against the risk difference of moderate-to-severe PVL, showing higher 30-day mortality rates with higher incidence of moderate-to-severe PVL (beta = 0.016; P = 0.035) ( Figure 5b); J. Clin. Med. 2020, 9, x  (6) 3.6 All-Cause Mortality A random-effects meta-regression was fitted, counter-opposing all-cause mortality risk ratio against the risk difference of moderate-to-severe PVL; there was a trend for higher 30-day mortality rates with higher incidence of moderate-to-severe PVL (beta = 0.023; P = 0.093) ( Figure 5b); Should be replaced with: A random-effects meta-regression was fitted, counter-opposing all-cause mortality risk ratio against the risk difference of moderate-to-severe PVL, showing higher 30-day mortality rates with higher incidence of moderate-to-severe PVL (beta = 0.016; P = 0.035) ( Figure 5b); (b) Figure 5. Individual and summary risk ratios with corresponding 95% confidence intervals for the comparison of ACURATE neo vs SAPIEN 3 in the analysis of (a) 30-day all-cause mortality; (b and c) meta regression analyses.
(7) 4. Discussion The abovementioned improvements seen in next-generation devices seem not to be the case with ACURATE neo; in the meta-analysis, we found 11.7% incidence of moderate-to-severe PVL in the ACURATE neo arm, nearly fourfold higher than in SAPIEN 3 and mild PVL in 45.5% cases, translating into 60% increased risk.
Should be replaced with: (7) 4. Discussion The abovementioned improvements seen in next-generation devices seem not to be the case with ACURATE neo; in the meta-analysis, we found 11.7% incidence of moderate-to-severe PVL in the ACURATE neo arm, nearly fourfold higher than in SAPIEN 3 and mild PVL in 45.5% cases, translating into 60% increased risk.
Should be replaced with: The abovementioned improvements seen in next-generation devices seem not to be the case with ACURATE neo; in the meta-analysis, we found 7.6% incidence of moderate-to-severe PVL in the ACURATE neo arm, over 3-fold higher than in SAPIEN 3 and mild PVL in 45.5% cases, translating into 60% increased risk.
(8) 5. Conclusions Moderate-to-severe PVL rates were, however, higher in ACURATE neo valve and were indirectly associated with increased 30-day all-cause mortality.
Should be replaced with: Moderate-to-severe PVL rates were, however, higher in ACURATE neo valve and were associated with increased 30-day all-cause mortality.
The incorrect copying of the numerical data before statistical calculations does not affect the results presented in the paper other than what is stated in the conclusions. The authors apologize to the readers for any inconvenience caused by these changes. It is important to state that this correction does not affect our study's results and involves no changes in the remaining data supporting our results. The original manuscript will remain online on the article webpage, with reference to this Correction.

Conflicts of Interest:
The authors declare no conflict.